Table 1.
Patient characteristics.
| Characteristics | No. of patients |
|---|---|
| All | 70 (100%) |
| Sex | |
| Male | 27 (39%) |
| Female | 43 (61%) |
| Age | |
| ≤29 | 8 (11%) |
| 30–39 | 10 (14%) |
| 40–49 | 31 (44%) |
| 50–59 | 15 (21%) |
| 60+ | 6 (9%) |
| Tissue molecular testing method | |
| WGS | 29 (41%) |
| WES | 41 (59%) |
| RNAseq | 55 (79%) |
| Methylome | 55 (79%) |
| Histologic diagnosis | |
| Adenocarcinoma | 43 (61%) |
| Squamous cell carcinoma | 9 (13%) |
| Neuroendocrine tumor | 5 (7%) |
| Melanoma | 3 (4%) |
| Poorly differentiated carcinoma | 3 (4%) |
| Undifferentiated carcinoma | 3 (4%) |
| Carcinoma, not otherwise specified | 2 (3%) |
| Moderately differentiated carcinoma | 1 (1%) |
| Sarcoma | 1 (1%) |
| Number of metastatic sites | |
| 1 | 24 (34%) |
| 2 | 20 (29%) |
| 3 | 12 (17%) |
| 4 | 11 (16%) |
| 5 or more | 2 (3%) |
| Location of disease | |
| Liver | 39 (56%) |
| Lymph nodes | 36 (51%) |
| Bones | 21 (30%) |
| Lung | 15 (21%) |
| Peritoneum | 14 (20%) |
| Other | 25 (36%) |
| MTB recommendations | |
| Therapies recommended | 56 (80%) |
| Therapies applied | 20 (29%) |
| Number of previous systemic therapies | |
| 0 | 10 (14%) |
| 1 | 26 (37%) |
| 2 | 17 (24%) |
| 3 | 5 (7%) |
| 4 or more | 11 (16%) |
Cohort description including sex and age distribution, method of molecular analysis and summation of (applied) tumor board recommendations. Number of previous therapies counted until sample submission. Percentages may not total 100 due to rounding.
WGS whole-genome sequencing, WES whole-exome sequencing, MTB molecular tumor board.